Anixa Biosciences (ANIX) Non-Current Deffered Revenue (2011 - 2012)
Anixa Biosciences' Non-Current Deffered Revenue came in at $235,981 for fiscal Q1 2012 (quarter ended Jan 31, 2012), down 51.1% from the prior quarter.
Powered by 
Analysis
Anixa Biosciences (ANIX) Non-Current Deffered Revenue (2011 - 2012) Analysis & Trends
At the end of FY2011 (ended Oct 31, 2011), Anixa Biosciences' Non-Current Deffered Revenue was $482,651.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | - |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | - |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | - |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | - |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | - |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | - |
| 10 | Anixa Biosciences | 96.15 Mn | 81.01 Mn | - | - |
API Access
Anixa Biosciences Non-Current Deffered Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ANIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-deffered-revenue", "ticker": "ANIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ANIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();